Pharmaceutical Benefits Scheme - new and amended listings
Description of the measure
Some new and amended listings are being added to the Pharmaceutical Benefits Scheme (PBS). These changes give eligible Australians and overseas visitors more affordable access to vital medicines.
From 1 July 2015 the new listings are:
- ranibizumab and aflibercept – for the treatment of diabetic macular oedema and central retinal vein occlusion
- trastuzumab, pertuzumab and trastuzumab emtansine – for the treatment of patients with HER2 positive metastatic breast cancer
From 1 August 2015 the new listing is:
- trametinib – for the treatment of melanoma in patients with BRAF mutation
From 1 July 2016 the amended listing is:
- Blood Glucose Test Strip – to restrict the access of Blood Glucose Test Strips provided to people with type 2 diabetes not using insulin who are initiating or require changes to existing diabetes management (previously unrestricted)
Questions and answers
Who is affected by this measure
Australians and eligible overseas patients who receive PBS medicines. Health professionals, including pharmacists will also be affected.
Who is eligible for this measure
The Schedule of Pharmaceutical Benefits has been updated to show the new and amended listings. Health professionals will decide if their patient is eligible under the restriction criteria listed in the Schedule of Pharmaceutical Benefits.
The date this measure will start and finish
The new and amended listings on the Pharmaceutical Benefits Schedule will have individual start dates identified in the description of the measure. The measure is ongoing.